Nanosphere, Inc. Logo

Nanosphere Verisens(TM) Ultra-Sensitive PSA Assay Highlighted at American Urological Association Annual Meeting

| Source: Nanosphere, Inc.

NORTHBROOK, Ill., June 2, 2010 (GLOBE NEWSWIRE) -- At the annual meeting of the American Urological Association (AUA), data using the Nanosphere Verisens™ ultra-sensitive PSA assay (research use only) will be highlighted as one of less than 40 abstracts that were singled out by the Association for a special session for journalists.

William Catalona, MD, Northwestern University, will present data from more than 400 patients demonstrating this assay may be valuable in stratifying recurrence risk and monitoring male response to adjuvant therapy following radical prostatectomy.

The abstract will be shared during the special session on Wednesday, June 2 at 9:30 a.m. PDT. The 105th Annual Scientific Meeting of the American Urological Association is being held in San Francisco, CA from May 29 to June 3, 2010.

The Verisens™ PSA assay tests for a single, well-known biomarker in blood. Nanosphere says the test has a number of advantages over other methods. A small amount of blood is used, rather than biopsied tissue. Using a single biomarker does not require complex algorithms in contrast to some multi-marker approaches. Moreover, testing using Nanosphere's ultra-sensitive PSA assay will be more cost effective.

For this research-use-only (RUO) Verisens™ PSA assay, Nanosphere provides testing as a service and has tested thousands of RUO patient samples for universities, commercial partners and for its internal research program for cancer biomarkers.

In addition to providing this PSA assay as a service, Nanosphere also provides a research-use-only cardiotoxicity assay for assessment of cancer therapeutics. The assay is based on an extremely sensitive human troponin assay. There is also a similar assay for rat troponin useful during pre-clinical studies.

Nanosphere is engaged in other cancer research and validation for protein biomarkers, independently and with commercial collaborations.

About Verisens™ PSA (RUO)

Verisens™ PSA is an in-vitro diagnostic assay for the high-sensitivity detection and quantification of prostate specific antigen (PSA). The assay was developed in collaboration with the International Institute for Nanotechnology at Northwestern University. Currently, it is intended to be performed as a testing service for research use only (see research-use notification below).

For additional information regarding the PSA assay, please contact Nanosphere at

For additional information regarding the cardiotoxicity assay, please contact Nanosphere at

For additional information regarding the cancer protein biomarkers and commercial collaborations, please contact Nanosphere at


Nanosphere, Inc. is required by the U.S. Food and Drug Administration (FDA) to certify in writing that its customers, who purchase or who are supplied with products labeled "For Research Use Only," acknowledge and understand that such products are not for use in diagnostic or therapeutic procedures. Tests performed with in vitro products intended for "Research Use Only" are tests used in a preclinical or nonclinical setting. While research tests may be performed using either clinical or nonclinical materials, research use devices have no intended clinical use and the testing performed is not designed to provide data addressing or demonstrating safety and effectiveness. We advise our customers to monitor the use of these products, to ensure that they are used for research purposes only. Please contact Nanosphere if you have questions.

About Nanosphere, Inc.

Nanosphere (Nasdaq:NSPH) develops, manufactures and markets an advanced molecular diagnostics platform, the Verigene® system, for ultra-sensitive protein, human genetic and infectious disease detection. This easy to use and cost effective platform enables simple, low cost and highly sensitive testing on a single platform. Nanosphere is based in Northbrook, IL. Additional information is available at

The Nanosphere, Inc. logo is available at

Nanosphere, Inc.
Winton Gibbons
(847) 400-9029

The Torrenzano Group
Media and Investors:
Ed Orgon